Permira Starts Neuraxpharm Sale, Lenders Prep €1.5 Billion Debt

Private equity firm Permira has kicked off the sale of German pharmaceutical company Neuraxpharm, with lenders readying debt financing of as much as €1.5 billion ($1.8 billion) for potential bidders.

Jefferies and JPMorgan are advising on the potential sale, according to people familiar with the matter who asked not to be identified because the deal is private. The deadline for non-binding offers is Feb. 5, one of the people said.